Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus : Impact of Hepatitis C Virus Treatment. / Mocroft, Amanda; Lundgren, Jens; Gerstoft, Jan; Rasmussen, Line D; Bhagani, Sanjay; Aho, Inka; Pradier, Christian; Bogner, Johannes R; Mussini, Christina; Uberti Foppa, Caterina; Maltez, Fernando; Laguno, Montse; Wandeler, Gilles; Falconer, Karolin; Trofimova, Tatyana; Borodulina, Elena; Jevtovic, Djordje; Bakowska, Elzbieta; Kase, Kerstin; Kyselyova, Galina; Haubrich, Richard; Rockstroh, Jürgen K; Peters, Lars; EuroSIDA study.

In: Clinical Infectious Diseases, Vol. 70, No. 10, 05.2020, p. 2131-2140.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Mocroft, A, Lundgren, J, Gerstoft, J, Rasmussen, LD, Bhagani, S, Aho, I, Pradier, C, Bogner, JR, Mussini, C, Uberti Foppa, C, Maltez, F, Laguno, M, Wandeler, G, Falconer, K, Trofimova, T, Borodulina, E, Jevtovic, D, Bakowska, E, Kase, K, Kyselyova, G, Haubrich, R, Rockstroh, JK, Peters, L & EuroSIDA study 2020, 'Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment', Clinical Infectious Diseases, vol. 70, no. 10, pp. 2131-2140. https://doi.org/10.1093/cid/ciz601

APA

Mocroft, A., Lundgren, J., Gerstoft, J., Rasmussen, L. D., Bhagani, S., Aho, I., Pradier, C., Bogner, J. R., Mussini, C., Uberti Foppa, C., Maltez, F., Laguno, M., Wandeler, G., Falconer, K., Trofimova, T., Borodulina, E., Jevtovic, D., Bakowska, E., Kase, K., ... EuroSIDA study (2020). Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clinical Infectious Diseases, 70(10), 2131-2140. https://doi.org/10.1093/cid/ciz601

CBE

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L, EuroSIDA study. 2020. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clinical Infectious Diseases. 70(10):2131-2140. https://doi.org/10.1093/cid/ciz601

MLA

Vancouver

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I et al. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clinical Infectious Diseases. 2020 May;70(10):2131-2140. https://doi.org/10.1093/cid/ciz601

Author

Mocroft, Amanda ; Lundgren, Jens ; Gerstoft, Jan ; Rasmussen, Line D ; Bhagani, Sanjay ; Aho, Inka ; Pradier, Christian ; Bogner, Johannes R ; Mussini, Christina ; Uberti Foppa, Caterina ; Maltez, Fernando ; Laguno, Montse ; Wandeler, Gilles ; Falconer, Karolin ; Trofimova, Tatyana ; Borodulina, Elena ; Jevtovic, Djordje ; Bakowska, Elzbieta ; Kase, Kerstin ; Kyselyova, Galina ; Haubrich, Richard ; Rockstroh, Jürgen K ; Peters, Lars ; EuroSIDA study. / Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus : Impact of Hepatitis C Virus Treatment. In: Clinical Infectious Diseases. 2020 ; Vol. 70, No. 10. pp. 2131-2140.

Bibtex

@article{4c2e37782f994f66b32ae50f4c75c722,
title = "Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment",
abstract = "BACKGROUND: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.METHODS: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).RESULTS: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.CONCLUSIONS: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.",
author = "Amanda Mocroft and Jens Lundgren and Jan Gerstoft and Rasmussen, {Line D} and Sanjay Bhagani and Inka Aho and Christian Pradier and Bogner, {Johannes R} and Christina Mussini and {Uberti Foppa}, Caterina and Fernando Maltez and Montse Laguno and Gilles Wandeler and Karolin Falconer and Tatyana Trofimova and Elena Borodulina and Djordje Jevtovic and Elzbieta Bakowska and Kerstin Kase and Galina Kyselyova and Richard Haubrich and Rockstroh, {J{\"u}rgen K} and Lars Peters and {EuroSIDA study} and {\O}stergaard, {Lars J{\o}rgen}",
note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",
year = "2020",
month = may,
doi = "10.1093/cid/ciz601",
language = "English",
volume = "70",
pages = "2131--2140",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus

T2 - Impact of Hepatitis C Virus Treatment

AU - Mocroft, Amanda

AU - Lundgren, Jens

AU - Gerstoft, Jan

AU - Rasmussen, Line D

AU - Bhagani, Sanjay

AU - Aho, Inka

AU - Pradier, Christian

AU - Bogner, Johannes R

AU - Mussini, Christina

AU - Uberti Foppa, Caterina

AU - Maltez, Fernando

AU - Laguno, Montse

AU - Wandeler, Gilles

AU - Falconer, Karolin

AU - Trofimova, Tatyana

AU - Borodulina, Elena

AU - Jevtovic, Djordje

AU - Bakowska, Elzbieta

AU - Kase, Kerstin

AU - Kyselyova, Galina

AU - Haubrich, Richard

AU - Rockstroh, Jürgen K

AU - Peters, Lars

AU - EuroSIDA study

AU - Østergaard, Lars Jørgen

N1 - © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2020/5

Y1 - 2020/5

N2 - BACKGROUND: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.METHODS: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).RESULTS: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.CONCLUSIONS: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.

AB - BACKGROUND: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.METHODS: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).RESULTS: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.CONCLUSIONS: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.

U2 - 10.1093/cid/ciz601

DO - 10.1093/cid/ciz601

M3 - Journal article

C2 - 31504296

VL - 70

SP - 2131

EP - 2140

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -